These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30309623)

  • 1. [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
    Zaibet S; Vauchier C; Khoudour N; Roulleaux Dugage M; Korb-Savoldelli V; Alexandre J; Blanchet B; Goldwasser F; Thomas-Schoemann A; Bellesoeur A
    Bull Cancer; 2018 Nov; 105(11):1102-1109. PubMed ID: 30309623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of individualized dosing in oncology: are we there yet?].
    Joerger M
    Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.
    Groenland SL; Mathijssen RHJ; Beijnen JH; Huitema ADR; Steeghs N
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1309-1318. PubMed ID: 31175385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
    Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
    Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecules, big impact: 20 years of targeted therapy in oncology.
    Bedard PL; Hyman DM; Davids MS; Siu LL
    Lancet; 2020 Mar; 395(10229):1078-1088. PubMed ID: 32222192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steps forward for cancer precision medicine.
    Salgado R; Moore H; Martens JWM; Lively T; Malik S; McDermott U; Michiels S; Moscow JA; Tejpar S; McKee T; Lacombe D;
    Nat Rev Drug Discov; 2018 Jan; 17(1):1-2. PubMed ID: 29170471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
    Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
    Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.
    Liewer S; Huddleston AN
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):453-64. PubMed ID: 25683755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of targeted anticancer therapy.
    Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
    Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
    van Leeuwen RW; van Gelder T; Mathijssen RH; Jansman FG
    Lancet Oncol; 2014 Jul; 15(8):e315-26. PubMed ID: 24988935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Personalized medicine for oral molecular-targeted anticancer drugs].
    Miura M
    Nihon Yakurigaku Zasshi; 2019; 153(2):73-78. PubMed ID: 30745517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature.
    Fahmy A; Hopkins AM; Sorich MJ; Rowland A
    Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):803-821. PubMed ID: 34278936
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
    Cardoso E; Csajka C; Schneider MP; Widmer N
    Clin Pharmacokinet; 2018 Jan; 57(1):1-6. PubMed ID: 28634655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study].
    Torrecillas S; Perrot E; Gérinière L; Locatelli-Sanchez M; Laffay L; Souquet PJ; Couraud S
    Rev Pneumol Clin; 2016 Feb; 72(1):25-34. PubMed ID: 26210879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualization of anticancer therapy; molecular targets of novel drugs in oncology].
    Regulska K; Stanisz B; Regulski M
    Postepy Hig Med Dosw (Online); 2012 Nov; 66():855-67. PubMed ID: 23175342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Targeted therapy in thyroid cancer: Towards a treatment card].
    Lkhoyaali S; Benhmida S; Ait Elhaj M; Layachi M; Bensouda Y; Errihani H
    Pathol Biol (Paris); 2015 Feb; 63(1):1-6. PubMed ID: 25555494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.